Peter Diamandis × Martine Rothblatt

United Therapeutics has four thymus shots on goal, including an FDA-approved xenothymus program and newly acquired Thymmune, making thymic replacement Rothblatt’s “most practical pathway” to LEV in the 2030s.Its xeno-kidney trial is mid-flight, facilities are slated for Rochester in August and Houston in October, and xeno-heart moved to Phase 3 after two patients survived 60 days without heart failure, with IVIVA trials starting in 2028.

Jorge Conde × Stéphane Bancel

Moderna and Merck’s personalized mRNA cancer vaccine met its Phase 3 primary endpoint in melanoma and also hit distant metastasis-free survival at the first interim analysis, with patient availability hoped for in 2027.Phase 2 showed 50% five-year recurrence-free survival versus Keytruda alone and 80% disease-free; inside-cell antigen presentation and a Marlborough facility capable of tens of thousands of doses support scale, while pricing and 20% nonresponse remain watchpoints.

Yushan × 英博

Moderna8月19日单日上涨177%，市场重估焦点转向肿瘤疫苗的增长与定价空间。INTerpath-001试验显示，个性化疫苗联合Keytruda的无复发生存达统计学显著；但OS、HR及亚组数据未披露，商业化仍取决于4至6周生产与耗材成本。

Ben Lamm × Molly O'Shea

Colossal’s woolly mice validated mammoth-editing in 30 days, with 100% healthy births and predicted phenotypes.With $635M raised, its screwworm solution could eradicate the problem in six to seven months versus $1.5B in taxpayer spending over eight years, pending permits.Astromec uses evolutionary-genomics AI for drug discovery; another extinct species may arrive within 12 months, but the target remains undisclosed.

Sarah Guo × Max Hodak

Prima won CE marketing approval in Europe in July, with commercial sales expected in coming weeks after trials let patients with macular degeneration complete Sudoku, crosswords, and read books.Science acquired Pixium’s Stanford-originated implant after about two years, calling it “by far the state-of-the-art”; pricing is unset, while future versions could improve color and expand the population from hundreds of thousands to millions.

李翔 × 夏宁

夏宁称，化学合成AI已达到“十年工作经验化学家”水平，五分钟可跑出客户耗时一两个月设计的路线。合成是DMTA循环瓶颈，若提速十到二十倍，新药和新材料研发通量或提高十到二十倍。商业化需白盒解释、验证和约束，并持续用智能调度压低token成本；SaaS与智能体将长期共存。

曹原

Discovery Loop由Jeff Dean、Oriol、Sanjay和Quoc创立，显示AI for Science正进入爆发期。代码、数学与agent harness可支持假设、实验、分析和迭代，但verification仍是瓶颈，生物制药或率先商业化。

RJ Honicky × Matt McPartlon × Neil Patil

Chai Discovery is commercializing a neutral modeling and product layer for pharma rather than developing its own drugs, with partnerships including Eli Lilly, Pfizer, Novartis, and Genentech.Chai-2 designed antibodies against 50 targets, finding binders for about half with an average binding hit rate of around 20%, while enabling GPCR agonists and multispecific formats traditional screening struggles to produce.The opportunity depends on improving developability and epitope prediction, but compute scarcity, validation latency, and talent shortages remain structural constraints as Chai scales its platform.

Andrew Walker × Paul Cerro

Cerro’s HIMS thesis shifts attention from peptide launches to the data and labs layer: subscriber counts have “barely grown” for three quarters, making retention the lever for LTV and payback.The August 10 print will test Eucalyptus-driven revenue upside against lower EBITDA guidance, the first full Novo Nordisk partnership quarter, and execution by management Cerro says he does not trust.

Andy Beam × Rafa Gómez-Bombarelli

Lila is betting that controlled experiments can become AI’s next internet-scale training corpus, with nature providing verifiable rewards and an information-gain-driven lab turning experiments into a compounding model moat.Lila reports a six-month, two- or three-person in vivo CAR-T program versus roughly six years and $100 million, but clinical translation, scale-up, regulation, and 5–6% model FLOPs utilization remain key watchpoints.